123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.

@article{Schwarz1998123IIBZMBC,
  title={123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.},
  author={Johannes Schwarz and Klaus Tatsch and Thomas Gasser and Guy Arnold and Oliver Pogarell and G. K{\"u}nig and Wolfgang Hermann Oertel},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={1998},
  volume={13 1},
  pages={16-9}
}
We performed a prospective clinical follow up (mean follow up, 36 months; range, 24-56 months) of 65 patients with de novo parkinsonism in whom imaging of dopamine D2 receptors was performed before the initiation of dopaminomimetic therapy by means of 123I-iodobenzamide-single-photon-emission computed tomography (IBZM-SPECT). The results of IBZM-SPECT were compared with the long-term response to dopaminomimetic drugs, the development of motor fluctuations, and the development of clinical signs… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Early-stage [123I]β-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson’s disease

European Journal of Nuclear Medicine and Molecular Imaging • 2004
View 9 Excerpts
Highly Influenced

Imaging synucleinopathies.

Movement disorders : official journal of the Movement Disorder Society • 2016

Similar Papers

Loading similar papers…